Key Differences Between Candida Glabrata and Albicans

Candida glabrata and Candida albicans are the two most common causes of serious Candida infections, yet they are surprisingly distant relatives that cause disease through fundamentally different biological strategies. C. albicans remains the most frequent culprit in candidemia worldwide and is classified as a critical priority pathogen, while C. glabrata has risen to become the second most common cause in many regions and is considered a high-priority pathogen.¹ Despite sharing a genus name, the two organisms differ in their genetics, their physical form, how they evade the immune system, and how they resist antifungal drugs. Those differences matter for diagnosis and treatment.

They Are Not Close Relatives

One of the most counterintuitive facts about these two fungi is that C. glabrata is more closely related to brewer’s yeast (Saccharomyces cerevisiae) than it is to C. albicans.² The two species were lumped together under the Candida umbrella largely because they both cause similar-looking infections in humans, not because they share a recent common ancestor. Their evolutionary paths diverged long ago, which explains why their toolkits for infecting people look so different. In recent years, taxonomists have reclassified C. glabrata as Nakaseomyces glabratus, though most clinical labs and guidelines still use the older name.

Shape-Shifting Versus Staying Small

C. albicans is famous for switching between yeast and hyphal (filamentous) forms. Those long thread-like hyphae can physically pierce tissue, helping the organism invade the lining of the gut, the mouth, or the bloodstream. This shape-shifting ability is one of its primary weapons.

C. glabrata does not form true hyphae. It grows exclusively as small, round blastoconidia, which are simple budding yeast cells.³ That lack of a filamentous form initially led researchers to assume it was a less dangerous organism. Clinical experience has proven otherwise. C. glabrata compensates with other survival strategies, including a remarkable ability to persist inside immune cells and a tendency to resist common antifungal drugs.

Genome and Genetic Architecture

At the DNA level, the two species are organized differently. C. albicans carries a diploid genome, meaning it has two copies of each chromosome. That genome is highly dynamic, capable of large-scale chromosomal rearrangements and extra or missing chromosomes, and these changes can drive drug resistance and virulence.⁴ C. glabrata, by contrast, is haploid, carrying only one copy of each chromosome.³ Having a single set of genes means that a single mutation in a drug-target gene can immediately change the organism’s behavior; there is no second, unmutated copy to mask the effect. This structural difference helps explain why C. glabrata can develop drug resistance so rapidly during treatment.

Different Weapons for Sticking to Tissue

Both species need to adhere to human tissue to establish an infection, but they use different molecular machinery to do it. C. albicans deploys a family of adhesion proteins, including ALS (agglutinin-like sequence) proteins and HWP1 (hyphal wall protein 1), which are tied to its ability to form hyphae and build biofilms on catheters and mucosal surfaces.⁵

C. glabrata relies on a large family of surface lectins encoded by the EPA (epithelial adhesin) genes, which have no precise parallel in C. albicans.⁶ Regulation of these adhesins involves chromatin remodeling near the telomeres (chromosome tips), a mechanism borrowed from its close relative, brewer’s yeast. The EPA genes can be switched on and off in a context-dependent way, giving C. glabrata flexibility in how and where it attaches to host cells.

The two species also differ in their secreted enzymes. C. albicans produces a well-studied set of secreted aspartic proteases (Saps) that help it break down host tissue. C. glabrata instead expresses a distinct group of cell-surface aspartic proteases called yapsins, which play roles in immune modulation and biofilm formation rather than direct tissue destruction.⁷

Two Very Different Immune Evasion Playbooks

When a macrophage (one of the body’s front-line immune cells) swallows C. albicans, the fungus quickly shifts into hyphal mode, physically puncturing its way out. The intracellular phase is short and violent. C. glabrata takes the opposite approach. Instead of fighting its way out, it hunkers down and survives inside the macrophage for an extended period, with host cells not bursting until two to three days later.⁸ This slow-escape strategy appears to be a genuine adaptation. C. glabrata seems equipped for long-term containment within macrophage compartments, tolerating the acidic, nutrient-poor environment inside the cell.⁹

This difference has clinical implications. C. albicans infections tend to provoke a strong inflammatory response, because the immune system detects and reacts to hyphal invasion. C. glabrata infections can be more insidious, sometimes persisting at low levels before causing overt disease, especially in patients with weakened immune systems.

Both species have also evolved ways to dodge the complement system, an ancient branch of immunity that tags pathogens for destruction. Candida species can mask their cell wall components, recruit host regulatory proteins to their surfaces, and cleave complement proteins, all of which dampen the immune alarm.¹⁰ The specifics vary between the two species, but the broad strategy of “look less foreign” is shared.

Antifungal Resistance and Why It Matters for Treatment

This is where the clinical rubber meets the road. C. albicans is generally susceptible to fluconazole and other azole antifungals, which work by blocking an enzyme involved in building the fungal cell membrane. Most C. albicans bloodstream infections can be treated with fluconazole if the isolate tests susceptible.

C. glabrata is a different story. It has intrinsically low susceptibility to fluconazole, and it can develop outright resistance during treatment.¹¹ The primary mechanism behind this resistance is not a change in the drug’s target enzyme (ERG11, the enzyme azoles are designed to block). Instead, C. glabrata ramps up efflux pumps, molecular machines that actively pump the drug back out of the cell before it can work. In one study, the vast majority of azole-resistant clinical isolates showed large increases in the expression of the CDR1 and CDR2 efflux pump genes, while the drug target gene itself showed no mutation or increased expression.¹² In some isolates, a third pump gene called SNQ2 was also upregulated, providing yet another escape route for the drug.¹²

Because of this intrinsic resistance pattern, the echinocandin class of antifungals (drugs like caspofungin, micafungin, and anidulafungin) is generally preferred as first-line therapy for C. glabrata bloodstream infections. Echinocandins work by blocking the enzyme that builds the fungal cell wall. But C. glabrata can develop resistance to echinocandins too, through mutations in the FKS1 and FKS2 genes that encode the drug target. In a large screening of over a thousand C. glabrata isolates, 51 were found to carry FKS hot spot mutations, and virtually all of them tested resistant to at least one echinocandin.¹³ These mutations reduce the drug’s ability to inhibit the target enzyme by several orders of magnitude.¹⁴

When a C. glabrata isolate is resistant to both azoles and echinocandins, clinicians are left with very limited options. This multidrug resistance potential is one of the main reasons C. glabrata demands careful attention in hospital settings.

How Treatment Guidelines Differ

The Infectious Diseases Society of America (IDSA) guidelines reflect these resistance differences directly. For candidemia caused by C. albicans, fluconazole remains a standard step-down option once the patient is stable. For C. glabrata, switching to fluconazole is recommended only when susceptibility testing confirms the isolate is susceptible, and even then at a higher dose of 800 mg daily. Voriconazole is another option, but again only with confirmed susceptibility.¹⁵

The differences also show up in the management of mucosal infections. For C. glabrata vulvovaginitis that does not respond to oral azoles, the IDSA recommends alternatives that would rarely be needed for C. albicans:

Intravaginal boric acid: 600 mg daily in a gelatin capsule for 14 days
Nystatin suppositories: 100,000 units daily for 14 days
Topical flucytosine cream: 17% concentration, alone or combined with 3% amphotericin B cream, daily for 14 days

These regimens underscore how much harder C. glabrata mucosal infections can be to clear when first-line azole therapy fails.¹⁵

Iron, Metabolism, and Nutrient Scavenging

Inside the human body, iron is tightly locked away in proteins like transferrin, ferritin, and hemoglobin. Any pathogen that wants to grow in human tissue needs to steal iron from these stores, and the two Candida species go about it very differently.

C. albicans can extract iron from a wide variety of host sources, including transferrin and hemoglobin. C. glabrata is much more restricted; it cannot grow on transferrin or hemoglobin at all. Instead, it relies primarily on ferritin and free iron, and even that ability depends on the pH of its environment.¹⁶

The mechanism of iron uptake is also unusual. Most fungi, including C. albicans and brewer’s yeast, use enzymes on their cell surface (ferric reductases) to convert iron into a form they can absorb. C. glabrata lacks detectable surface ferric reductase activity altogether. Instead, it appears to secrete a small molecule that performs the same chemical job outside the cell.¹⁶ This stripped-down iron acquisition strategy may reflect C. glabrata‘s adaptation to the specific niches it inhabits in the human body, where free iron and ferritin are more available than hemoglobin.

Who Gets Which Infection

C. albicans causes infections across all age groups and patient populations. It is the dominant species in mucosal candidiasis (oral thrush, vaginal yeast infections) and remains the leading cause of bloodstream Candida infections globally. C. glabrata, while found in all age groups, is notably more common in older patients. A large epidemiological survey in Latin America found that C. glabrata accounted for about 15% of candidemia in elderly patients, compared to roughly 3-5% in children and younger adults.¹⁷ This age skew likely reflects higher rates of azole exposure and underlying health conditions in older populations, which create selection pressure favoring the more resistant species.

Geographic patterns matter too. C. glabrata is proportionally more common in North America and northern Europe than in parts of Asia and Latin America, where C. tropicalis and C. parapsilosis tend to fill the “second most common” slot. These regional differences are thought to reflect variation in antifungal prescribing habits, as heavy azole use selects for species with intrinsic azole resistance.

Telling Them Apart in the Lab

From the clinician’s perspective, identifying which species is causing an infection is critical because it changes drug selection. Traditional culture-based methods can take days. Chromogenic agar media, which cause different Candida species to grow as differently colored colonies, offer a quicker presumptive identification. Newer formulations like CHROMagar Candida Plus can reliably identify C. albicans and screen for C. glabrata, though some other species can be misidentified as C. glabrata, so confirmatory testing is recommended.¹⁸

MALDI-TOF mass spectrometry, which identifies organisms by their protein fingerprint, has become the gold standard in many hospitals and correctly identified about 94% of strains tested in one evaluation.¹⁸ Molecular methods like multiplex PCR can go further, distinguishing not just C. albicans from C. glabrata but also closely related “cryptic” species within each group that look identical on standard culture but may differ in drug susceptibility.¹⁹

Phenotypic Switching as a Shared Survival Trick

Despite their many differences, the two species share at least one broad survival strategy: phenotypic switching. This is the ability of a genetically identical population to spontaneously produce cells with different observable traits, like altered colony appearance, surface protein profiles, or drug susceptibility. In C. albicans, the best-known form is the white-opaque switch, which affects mating ability and virulence. C. glabrata has its own version, toggling between white, light brown, and dark brown colony types. These switches are reversible and occur at high frequency, and they regulate genes involved in pathogenesis, including a metallothionein gene and a hemolysin gene.²⁰

The existence of phenotypic switching in both species, despite their evolutionary distance, suggests it confers a powerful advantage for any fungus living in a human host. It provides a way to rapidly diversify a population without waiting for genetic mutations, generating subpopulations that may be better suited to shifting conditions like changes in pH, nutrient availability, immune pressure, or antifungal exposure.⁶

When Both Species Show Up Together

In clinical practice, mixed infections involving both C. albicans and C. glabrata are not uncommon, especially in biofilms on catheters and medical devices. These coculture biofilms are structurally complex, with long C. albicans hyphae forming a scaffold and clusters of C. glabrata cells nestled within.⁵ The presence of C. glabrata can actually increase the expression of adhesion genes in C. albicans, potentially making the mixed biofilm stickier and harder to eradicate than either species alone would produce. Mixed infections pose a particular treatment challenge because the two species may require different antifungals, and a drug that clears one may leave the other free to expand.

1
PubMed Central. Candida albicans and Candida glabrata: global priority pathogens
2
FEMS Yeast Research. Evolution of regulatory networks in Candida glabrata: learning to live with the human host
3
PubMed Central. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans
4
PubMed. Genome plasticity in Candida albicans: A cutting-edge strategy for evolution, adaptation, and survival
5
PubMed Central. Relative Abundances of Candida albicans and Candida glabrata in In Vitro Coculture Biofilms Impact Biofilm Structure and Formation
6
PubMed. A yeast by any other name: Candida glabrata and its interaction with the host
7
Scientific Reports. Functional roles of purified yapsins from Candida glabrata in immune modulation and cross-species biofilm formation
8
PubMed Central. “Should I stay or should I go”-a kinase delays escape of Candida glabrata from macrophages
9
FEMS Yeast Research. Intracellular survival of Candida glabrata in macrophages: immune evasion and persistence
10
PubMed Central. Candidiasis: Insights into Virulence Factors, Complement Evasion and Antifungal Drug Resistance
11
PubMed Central. Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor
12
PubMed Central. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance
13
PubMed Central. Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance
14
PubMed Central. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint
15
Clinical Infectious Diseases. IDSA 2016 Clinical Practice Guideline Update for the Management of Candidiasis
16
PubMed Central. The Fungal Pathogen Candida glabrata Does Not Depend on Surface Ferric Reductases for Iron Acquisition
17
PLoS ONE. Epidemiology of Candidemia in Latin America: A Laboratory-Based Survey
18
PubMed. Evaluation of the CHROMagar Candida Plus medium for presumptive identification of yeasts and MALDI-TOF MS identification
19
PubMed Central. Identification of nine cryptic species of Candida albicans, C. glabrata, and C. parapsilosis complexes using one-step multiplex PCR
20
PubMed Central. Phenotypic switching in Candida glabrata involves phase-specific regulation of the metallothionein gene MT-II and the newly discovered hemolysin gene HLP